Lung transplantation and systemic sclerosis.

V. Rosas, John Conte, S. C. Yang, S. P. Gaine, M. Borja, F. M. Wigley, B. White, J. B. Orens

Research output: Contribution to journalReview article

80 Citations (Scopus)

Abstract

We performed lung transplantation in nine patients with Scleroderma related lung disease. Patient characteristics included: 7 (78%) females, 6 (67%) with limited and 3 (33%) with diffuse Scleroderma. Pulmonary fibrosis was present in 7 (78%) and pulmonary hypertension in 4 (44%). All patients were carefully screened by the Johns Hopkins and University of Maryland Scleroderma Center and only referred for transplantation when concomitant renal insufficiency (creatinine clearance < or = 50 ml/min), aspiration, and skin brakdown were excluded. When compared to a similar group of transplant patients with nonscleroderma lung disease (primary pulmonary fibrosis), there was no significant difference in post-transplant survival at four years (76.2 +/- 0.15% vs. 69.2% +/- 0.12%), mean annual incidence rate for acute rejection (0.14 +/- 0.14 vs. 0.47 +/- 0.13) and infection (viral 0.17 +/- 0.17 vs. 0.29 +/- 0.11) (bacterial 0.17 +/- 0.17 vs. 1.4 +/- 0.4) (fungal 0.99 +/- 0.69 vs. 0.36 +/- 0.16) or serum creatinine (1.55 +/- 0.34 mg/dl vs. 1.15 +/- 0.09 mg/dl). We conclude that lung transplantation is viable option for carefully selected patients with scleroderma related lung disease.

Original languageEnglish (US)
Pages (from-to)38-43
Number of pages6
JournalAnnals of transplantation : quarterly of the Polish Transplantation Society
Volume5
Issue number3
StatePublished - Jan 1 2000

Fingerprint

Lung Transplantation
Systemic Scleroderma
Lung Diseases
Pulmonary Fibrosis
Creatinine
Transplants
Diffuse Scleroderma
Virus Diseases
Pulmonary Hypertension
Renal Insufficiency
Transplantation
Skin
Incidence
Serum

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Rosas, V., Conte, J., Yang, S. C., Gaine, S. P., Borja, M., Wigley, F. M., ... Orens, J. B. (2000). Lung transplantation and systemic sclerosis. Annals of transplantation : quarterly of the Polish Transplantation Society, 5(3), 38-43.
Rosas, V. ; Conte, John ; Yang, S. C. ; Gaine, S. P. ; Borja, M. ; Wigley, F. M. ; White, B. ; Orens, J. B. / Lung transplantation and systemic sclerosis. In: Annals of transplantation : quarterly of the Polish Transplantation Society. 2000 ; Vol. 5, No. 3. pp. 38-43.
@article{6fb16bee05be4c3a91b90eaf53699978,
title = "Lung transplantation and systemic sclerosis.",
abstract = "We performed lung transplantation in nine patients with Scleroderma related lung disease. Patient characteristics included: 7 (78{\%}) females, 6 (67{\%}) with limited and 3 (33{\%}) with diffuse Scleroderma. Pulmonary fibrosis was present in 7 (78{\%}) and pulmonary hypertension in 4 (44{\%}). All patients were carefully screened by the Johns Hopkins and University of Maryland Scleroderma Center and only referred for transplantation when concomitant renal insufficiency (creatinine clearance < or = 50 ml/min), aspiration, and skin brakdown were excluded. When compared to a similar group of transplant patients with nonscleroderma lung disease (primary pulmonary fibrosis), there was no significant difference in post-transplant survival at four years (76.2 +/- 0.15{\%} vs. 69.2{\%} +/- 0.12{\%}), mean annual incidence rate for acute rejection (0.14 +/- 0.14 vs. 0.47 +/- 0.13) and infection (viral 0.17 +/- 0.17 vs. 0.29 +/- 0.11) (bacterial 0.17 +/- 0.17 vs. 1.4 +/- 0.4) (fungal 0.99 +/- 0.69 vs. 0.36 +/- 0.16) or serum creatinine (1.55 +/- 0.34 mg/dl vs. 1.15 +/- 0.09 mg/dl). We conclude that lung transplantation is viable option for carefully selected patients with scleroderma related lung disease.",
author = "V. Rosas and John Conte and Yang, {S. C.} and Gaine, {S. P.} and M. Borja and Wigley, {F. M.} and B. White and Orens, {J. B.}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "5",
pages = "38--43",
journal = "Annals of Transplantation",
issn = "1425-9524",
publisher = "International Scientific Information, Inc.",
number = "3",

}

Rosas, V, Conte, J, Yang, SC, Gaine, SP, Borja, M, Wigley, FM, White, B & Orens, JB 2000, 'Lung transplantation and systemic sclerosis.', Annals of transplantation : quarterly of the Polish Transplantation Society, vol. 5, no. 3, pp. 38-43.

Lung transplantation and systemic sclerosis. / Rosas, V.; Conte, John; Yang, S. C.; Gaine, S. P.; Borja, M.; Wigley, F. M.; White, B.; Orens, J. B.

In: Annals of transplantation : quarterly of the Polish Transplantation Society, Vol. 5, No. 3, 01.01.2000, p. 38-43.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Lung transplantation and systemic sclerosis.

AU - Rosas, V.

AU - Conte, John

AU - Yang, S. C.

AU - Gaine, S. P.

AU - Borja, M.

AU - Wigley, F. M.

AU - White, B.

AU - Orens, J. B.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - We performed lung transplantation in nine patients with Scleroderma related lung disease. Patient characteristics included: 7 (78%) females, 6 (67%) with limited and 3 (33%) with diffuse Scleroderma. Pulmonary fibrosis was present in 7 (78%) and pulmonary hypertension in 4 (44%). All patients were carefully screened by the Johns Hopkins and University of Maryland Scleroderma Center and only referred for transplantation when concomitant renal insufficiency (creatinine clearance < or = 50 ml/min), aspiration, and skin brakdown were excluded. When compared to a similar group of transplant patients with nonscleroderma lung disease (primary pulmonary fibrosis), there was no significant difference in post-transplant survival at four years (76.2 +/- 0.15% vs. 69.2% +/- 0.12%), mean annual incidence rate for acute rejection (0.14 +/- 0.14 vs. 0.47 +/- 0.13) and infection (viral 0.17 +/- 0.17 vs. 0.29 +/- 0.11) (bacterial 0.17 +/- 0.17 vs. 1.4 +/- 0.4) (fungal 0.99 +/- 0.69 vs. 0.36 +/- 0.16) or serum creatinine (1.55 +/- 0.34 mg/dl vs. 1.15 +/- 0.09 mg/dl). We conclude that lung transplantation is viable option for carefully selected patients with scleroderma related lung disease.

AB - We performed lung transplantation in nine patients with Scleroderma related lung disease. Patient characteristics included: 7 (78%) females, 6 (67%) with limited and 3 (33%) with diffuse Scleroderma. Pulmonary fibrosis was present in 7 (78%) and pulmonary hypertension in 4 (44%). All patients were carefully screened by the Johns Hopkins and University of Maryland Scleroderma Center and only referred for transplantation when concomitant renal insufficiency (creatinine clearance < or = 50 ml/min), aspiration, and skin brakdown were excluded. When compared to a similar group of transplant patients with nonscleroderma lung disease (primary pulmonary fibrosis), there was no significant difference in post-transplant survival at four years (76.2 +/- 0.15% vs. 69.2% +/- 0.12%), mean annual incidence rate for acute rejection (0.14 +/- 0.14 vs. 0.47 +/- 0.13) and infection (viral 0.17 +/- 0.17 vs. 0.29 +/- 0.11) (bacterial 0.17 +/- 0.17 vs. 1.4 +/- 0.4) (fungal 0.99 +/- 0.69 vs. 0.36 +/- 0.16) or serum creatinine (1.55 +/- 0.34 mg/dl vs. 1.15 +/- 0.09 mg/dl). We conclude that lung transplantation is viable option for carefully selected patients with scleroderma related lung disease.

UR - http://www.scopus.com/inward/record.url?scp=0034566693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034566693&partnerID=8YFLogxK

M3 - Review article

C2 - 11147028

AN - SCOPUS:0034566693

VL - 5

SP - 38

EP - 43

JO - Annals of Transplantation

JF - Annals of Transplantation

SN - 1425-9524

IS - 3

ER -